Yokota Kana, Nozu Kandai, Minamikawa Shogo, Yamamura Tomohiko, Nakanishi Keita, Kaneda Hisashi, Hamada Riku, Nozu Yoshimi, Shono Akemi, Ninchoji Takeshi, Morisada Naoya, Ishimori Shingo, Fujimura Junya, Horinouchi Tomoko, Kaito Hiroshi, Nakanishi Koichi, Morioka Ichiro, Taniguchi-Ikeda Mariko, Iijima Kazumoto
Department of Pediatrics, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo, Kobe, 6500017, Japan.
Department of Pediatrics, Komatsu Municipal Hospital, Komatsu, Ishikawa, Japan.
Clin Exp Nephrol. 2017 Oct;21(5):877-883. doi: 10.1007/s10157-016-1352-y. Epub 2016 Oct 31.
X-linked Alport syndrome (XLAS) is a progressive, hereditary nephropathy. Although males with XLAS usually develop end-stage renal disease before 30 years of age, some men show a milder phenotype and possess somatic mosaic variants of the type IV collagen α5 gene (COL4A5), with severity depending on variant frequencies. In females, somatic mosaic variants are rarely reported in XLAS, and it is not clear what determines severity.
Two females with somatic mosaic mutations in COL4A5 with variant frequencies of 17.9 and 22.1% were detected using the next-generation sequencing. One patient only had hematuria. The other, however, had moderate proteinuria, which is a severe phenotype for a female XLAS patient of her age. The molecular mechanisms for the severe phenotype were investigated by examining variant frequencies in urinary sediment cells and X chromosome inactivation patterns, and by looking for modifier variants in podocyte-related genes using the next-generation sequencing.
The severe phenotype patient had a variant frequency of 36.6% in urinary sediment cells, which is not markedly high, nor did she show skewed X chromosome inactivation. However, she did have the heterozygous variant in COL4A3, which can affect severity.
Factors determining severity in female XLAS patients remain unclear. One studied patient with the somatic variant in COL4A5 showed a severe phenotype without skewed X chromosome inactivation, which might be derived from digenic variants in COL4A3 and COL4A5. Further studies are required to determine molecular mechanisms behind female XLAS resulting in the severe phenotype.
X连锁Alport综合征(XLAS)是一种进行性遗传性肾病。虽然患有XLAS的男性通常在30岁前发展为终末期肾病,但一些男性表现出较轻的表型,并拥有IV型胶原α5基因(COL4A5)的体细胞镶嵌变异,严重程度取决于变异频率。在女性中,XLAS很少报道体细胞镶嵌变异,且不清楚决定严重程度的因素是什么。
使用下一代测序检测到两名COL4A5体细胞镶嵌突变的女性,变异频率分别为17.9%和22.1%。一名患者仅有血尿。然而,另一名患者有中度蛋白尿,这对于她这个年龄的女性XLAS患者来说是严重的表型。通过检查尿沉渣细胞中的变异频率和X染色体失活模式,并使用下一代测序寻找足细胞相关基因中的修饰变异,来研究严重表型的分子机制。
严重表型患者尿沉渣细胞中的变异频率为36.6%,这并不明显高,她也没有显示出X染色体失活偏斜。然而,她确实有COL4A3的杂合变异,这可能会影响严重程度。
女性XLAS患者严重程度的决定因素仍不清楚。一名研究对象的COL4A5体细胞变异表现出严重表型,且没有X染色体失活偏斜,这可能源于COL4A3和COL4A5的双基因变异。需要进一步研究以确定导致女性XLAS严重表型的分子机制。